Abbreviations: Recurrent or metastatic (r/m), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), membranous nephropathy (MN), lupus nephritis (LN).
Notes: The trademarks and registered trademarks within are the property of their respective owners. *Greater China trial in preparation or under planning. Greater China = mainland China, Hong Kong, Macau and Taiwan, collectively. (1) Also launched in Hong Kong and Macau; (2) Commercially available in Hong Kong; (3) Greater China-only trial; (4) Also approved in Hong Kong and Taiwan; (5) Combination with carboplatin and KEYTRUDA +/- bevacizumab; (6) 1st line+ locally advanced or metastatic disease in solid tumors including colorectal cancer, pancreatic cancer, non-small cell lung cancer, and head and neck cancer; monotherapy and combination with KEYTRUDA and either carboplatin or cisplatin; (7) Global Phase 3 FORTITUDE-101 study has completed enrollment in June 2024; global Phase 3 FORTITUDE-102 study is enrolling; (8) Zai Lab has exclusive license to develop and commercialize SUL-DUR in mainland China, Hong Kong, Taiwan, Macau, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan; (9) Initiated enrollment of the proof-of-concept trials of LN and MN in China in February 2023.
Ongoing Clinical Trials
For more information about the above trials, please visit https://clinicaltrials.gov